Alnylam Pharmace. buy Commando
Start price
20.08.22
/
50%
€214.90
Target price
20.08.23
-
Performance (%)
-14.30%
End price
07.03.23
€184.16
Summary
This prediction ended on 07.03.23 with a price of €184.16. The prediction for Alnylam Pharmace. disappointed with a performance of -14.30%. Commando has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -25.039% | -25.039% | -47.629% | 12.663% |
| iShares Core DAX® | 2.334% | 1.011% | 10.406% | 61.226% |
| iShares Nasdaq 100 | 1.370% | -3.612% | 27.400% | 80.083% |
| iShares Nikkei 225® | 2.437% | -7.461% | 49.840% | 72.355% |
| iShares S&P 500 | 1.259% | 0.677% | 23.666% | 65.890% |
Comments by Commando for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.